Clinical Trial

Neoadjuvant Darovasertib in Primary Uveal Melanoma

Name: Neoadjuvant Darovasertib in Primary Uveal Melanoma — clinical trial record (NCT07015190)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)

Protocol Amendment History 1 change

notable Trial sites expanded: 87 -> 94 locations 2026-05-07

Trial Details

NCT Number	NCT07015190
Lead Sponsor	IDEAYA Biosciences
Conditions	Uveal Melanoma
Enrollment	520 participants
Start Date	2026-01-25
Primary Completion	2030-10 (estimated)
Study Completion	2031-03 (estimated)
Updated on ClinicalTrials.gov	2026-05-06